| Schedule of Basic and Diluted Earnings Per Share |
Shares used in the computation of the Company’s basic and diluted earnings per share are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (in thousands, except per share data) |
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
|
2026 |
|
2025 |
|
2026 |
|
2025 |
| Numerator |
|
|
|
|
|
|
|
|
| Net increase (decrease) in net assets resulting from operations |
|
$ |
93,568 |
|
|
$ |
119,685 |
|
|
$ |
266,251 |
|
|
$ |
248,909 |
|
| Less: Total distributions declared |
|
(87,969) |
|
|
(85,388) |
|
|
(262,652) |
|
|
(249,855) |
|
| Total Earnings (loss), net of total distributions |
|
5,599 |
|
|
34,297 |
|
|
3,599 |
|
|
(946) |
|
|
|
|
|
|
|
|
|
|
| Earnings (loss), net of distributions attributable to common shares |
|
5,555 |
|
|
34,042 |
|
|
3,568 |
|
|
(947) |
|
| Add: Distributions declared attributable to common shares |
|
87,267 |
|
|
84,752 |
|
|
260,320 |
|
|
247,749 |
|
| Numerator for basic change in net assets per common share |
|
92,822 |
|
|
118,794 |
|
|
263,888 |
|
|
246,802 |
|
| Add: Income impact of assumed conversion of 2028 Convertible Notes |
|
4,079 |
|
4,116 |
|
12,236 |
|
|
9,096 |
| Numerator for diluted change in net assets per common share |
|
$ |
96,901 |
|
|
$ |
122,910 |
|
|
$ |
276,124 |
|
|
$ |
255,898 |
|
|
|
|
|
|
|
|
|
|
| Denominator |
|
|
|
|
|
|
|
|
| Basic weighted average common shares outstanding |
|
185,989 |
|
180,360 |
|
184,767 |
|
175,633 |
| Incremental shares from assumed conversion of 2028 Convertible Notes |
|
13,387 |
|
13,387 |
|
13,387 |
|
10,015 |
| Common shares issuable |
|
702 |
|
611 |
|
683 |
|
603 |
| Weighted average common shares outstanding assuming dilution |
|
200,078 |
|
194,358 |
|
198,837 |
|
186,251 |
|
|
|
|
|
|
|
|
|
| Change in net assets per common share: |
|
|
|
|
|
|
|
|
| Basic |
|
$ |
0.50 |
|
|
$ |
0.66 |
|
|
$ |
1.43 |
|
|
$ |
1.41 |
|
| Diluted |
|
$ |
0.48 |
|
|
$ |
0.63 |
|
|
$ |
1.39 |
|
|
$ |
1.37 |
|
|
| Schedule of Number of Anti-diluted Shares as Calculated Based on Weighted Average Closing Price of Common Stock |
The calculation of change in net assets resulting from operations per common share assuming dilution, excludes all anti-dilutive shares. For the three and nine months ended September 30, 2026 and 2025, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
| Anti-dilutive Securities |
|
2026 |
|
2025 |
|
2026 |
|
2025 |
| Unvested common stock options |
|
45 |
|
1,527 |
|
160 |
|
1,217 |
|
|
|
|
|
|
|
|
|
| Unvested restricted stock awards |
|
33,068 |
|
— |
|
91,354 |
|
1,094 |
|
|
|
|
|
|
|
|
|
|